Entelexo Biotherapeutics GTM brain

Entelexo is developing engineered exosome therapeutics for autoimmune diseases, with potential future clinical use and development partnerships.

category

Investigational exosome therapeutics

market profile

  • text: Psoriasis, rheumatoid arthritis and Crohn's disease have complex immune pathways and continue to attract new therapeutic approaches.
  • text: The company reports human cell assays and lists planned animal and regulatory milestones through 2023; current development status is unverified.
  • text: Exosome-based therapeutics are a competitive research area with technical and clinical development risk.

personas

  • title: Pharmaceutical business development and licensing lead
    pains:
    • Sourcing differentiated immunology programs with credible translational evidence
    • Diligencing intellectual property, manufacturability and regulatory risk
  • title: Translational immunology research leader
    pains:
    • Addressing disease mechanisms that involve several cell types and pathways
    • Showing that cell assay results translate to in vivo disease models
  • title: Dermatologist or rheumatologist
    pains:
    • Patients with persistent disease despite available therapies
    • Need for well-controlled safety and efficacy data before considering an investigational treatment

icp

  • text: Potential partners are pharmaceutical and biotech organizations with immunology portfolios and capacity for preclinical development; this is an inference, not a disclosed customer segment.
  • text: Potential future clinical users include specialists treating psoriasis, rheumatoid arthritis and Crohn's disease, contingent on successful studies and regulatory authorization.

message pillars

  • text: Build a new therapeutic class using engineered exosomes.
  • text: Prototype candidates for multiple autoimmune indications.
  • text: Explore simultaneous communication with several disease-related cell types.

objections

  • objection: Human cell assays do not prove safety or efficacy in patients.
    response: Request current preclinical results and regulatory status; describe all candidates as investigational.
  • objection: Can engineered exosomes be produced consistently at scale?
    response: Request manufacturing, characterization, batch consistency and delivery data during diligence.
  • objection: How defensible is the platform?
    response: Review the patent estate, ownership, freedom to operate and indication-specific claims with counsel.

competitors

  • name: Evox Therapeutics
    why: Develops extracellular vesicle therapeutics and competes for development partners and resources in an adjacent modality.
  • name: Coya Therapeutics
    why: Develops immune regulatory approaches including Treg-derived exosomes and autoimmune programs; mechanisms differ.
  • name: Sonoma Biotherapeutics
    why: Develops Treg cell therapies for autoimmune diseases, an adjacent therapeutic strategy.

influencers

  • name: Milad Riazifar
    url: https://www.linkedin.com/in/miladriazifar
    why: Founder with exosome research expertise and a public professional profile.
  • name: Cameron Taylor
    url: https://www.cbinsights.com/company/entelexo-biotherapeutics
    why: Co-founder associated with exosome engineering and manufacturing.

keywords

  • engineered exosome therapeutics
  • autoimmune disease drug development
  • extracellular vesicle immunology
  • psoriasis investigational therapies
  • rheumatoid arthritis drug discovery
  • exosome drug delivery

voice

  • Scientific and mechanism focused
  • Ambitious about platform potential
  • Early-stage research oriented

signals

  • text: A pharma immunology team seeks external preclinical modalities or licensing opportunities.
  • text: A translational team is investigating multiple cellular pathways in autoimmune disease.

pricing

model: unknown

motion

unknown

confidence

low

Founders

  • name: MILAD RIAZIFAR
    title: Founder
    role: Founder
    bio: Dr. Riazifar has worked on stem cells over a decade and on exosomes a subclass of stem cell derived extracellular vesicles since 2012. During his Ph.D studies at the Stem Cell Research Center at the University of California Irvine, he pioneered a cell-free exosome-based approach to treat Multiple Sclerosis. At City of Hope, he was part of a clinical translation team initiating the world’s first clinical trial using stem cell exosomes for the treatment of type I diabetes.
  • name: Todd Schurr
    title: Founder
    role: Founder
    bio: Multidisciplinary engineer with diverse experience in cellular biology, electrical engineering, automotive, and more. To quote Einstein, I am "passionately curious" regarding just about everything.
  • name: Cameron Taylor
    title: Founder
    role: Founder
    bio: MSE in Biomedical Engineering from University of Michigan, Class of 2018 Co-Founder and CTO at Entelexo Biotherapeutics.

Back to YC companies